139 related articles for article (PubMed ID: 15154823)
1. Risk management : a European regulatory perspective.
Moseley JN
Drug Saf; 2004; 27(8):499-508. PubMed ID: 15154823
[TBL] [Abstract][Full Text] [Related]
2. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
Santoro A; Genov G; Spooner A; Raine J; Arlett P
Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
[TBL] [Abstract][Full Text] [Related]
3. [The new pharmacovigilance legislation in practice].
Broekmans AW; Mol PG
Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
[TBL] [Abstract][Full Text] [Related]
4. Factors distinguishing important identified risks from important potential risks in orphan and nonorphan drugs: An analysis of safety specifications of Japan and European Union risk management plans.
Hirota S; Yamaguchi T
Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1231-1238. PubMed ID: 30187590
[TBL] [Abstract][Full Text] [Related]
5. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
6. Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns.
Holm JEJ; Ruppert JG; Ramsden SD
Pharmaceut Med; 2022 Feb; 36(1):33-46. PubMed ID: 35099785
[TBL] [Abstract][Full Text] [Related]
7. Improving the Safety of Medicines in the European Union: From Signals to Action.
Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P
Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897
[TBL] [Abstract][Full Text] [Related]
8. Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU.
Butler D; Vucic K; Straus S; Cupelli A; Micallef B; Serracino-Inglott A; Borg JJ
Expert Opin Drug Saf; 2021 Jul; 20(7):815-826. PubMed ID: 33843379
[No Abstract] [Full Text] [Related]
9. New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014-2017.
Farcaş A; Măhălean A; Bulik NB; Leucuta D; Mogoșan C
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):1045-1051. PubMed ID: 30269618
[TBL] [Abstract][Full Text] [Related]
10. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
[TBL] [Abstract][Full Text] [Related]
11. Measuring the impact of the 2012 European pharmacovigilance legislation on additional risk minimization measures.
Francisca RDC; Zomerdijk IM; Sturkenboom MCJM; Straus SMJM
Expert Opin Drug Saf; 2018 Oct; 17(10):975-982. PubMed ID: 30107752
[TBL] [Abstract][Full Text] [Related]
12. A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee.
Pacurariu AC; Coloma PM; van Haren A; Genov G; Sturkenboom MC; Straus SM
Drug Saf; 2014 Dec; 37(12):1059-66. PubMed ID: 25398646
[TBL] [Abstract][Full Text] [Related]
13. A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.
Tanti A; Micallef B; Serracino-Inglott A; Borg JJ
Expert Opin Drug Saf; 2017 Jan; 16(1):65-76. PubMed ID: 27732110
[TBL] [Abstract][Full Text] [Related]
14. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
[TBL] [Abstract][Full Text] [Related]
15. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
[TBL] [Abstract][Full Text] [Related]
16. Pharmacovigilance in Israel - tools, processes, and actions.
Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
[TBL] [Abstract][Full Text] [Related]
17. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.
Tsintis P; La Mache E
Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824
[TBL] [Abstract][Full Text] [Related]
18. [Interpretation of Guidelines on Good Pharmacovigilance Practices for European Union].
Xie YM; Tian F
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2963-8. PubMed ID: 24471312
[TBL] [Abstract][Full Text] [Related]
19. Interest of pharmacoepidemiology in pharmacovigilance: Post-authorization safety studies in regulatory pharmacovigilance activity.
Abou Taam M; Ferard C; Rocle P; Maison P
Therapie; 2019 Apr; 74(2):301-306. PubMed ID: 30704766
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars: pharmacovigilance and risk management.
Zuñiga L; Calvo B
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
